These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 30153598)

  • 1. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
    Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    J Affect Disord; 2018 Jan; 225():709-714. PubMed ID: 28922734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
    Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
    Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
    Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.